Recent Updates
Recently added Catalysts
MRVI Neutral Sentiment

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Maravai LifeSciences Holdings, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $51.4 million. The company experienced a net loss of $(21.6) million but raised its full-year 2026 Adjusted EBITDA guidance to between $33 million and $35 million. This reflects ongoing financial challenges despite positive revenue growth.

Market Sentiment Analysis

POSITIVE FACTORS

  • Quarterly revenue reached $51.4 million.
  • Adjusted EBITDA guidance for 2026 raised to $33 million to $35 million.

CONCERNS & RISKS

  • Net loss reported at $(21.6) million.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli

Frequently Asked Questions

What was Maravai's revenue for Q2 2026?

Maravai reported a revenue of $51.4 million for the second quarter of 2026.

What was the net loss for Maravai in Q2 2026?

The net loss for Maravai in the second quarter of 2026 was $(21.6) million.

What is the updated Adjusted EBITDA guidance for 2026?

Maravai raised its full-year 2026 Adjusted EBITDA guidance to between $33 million and $35 million.

ShareAdd on Google
Tags: MRVI Viatris Investor Conferences Healthcare Maravai LifeSciences financial results 2026 earnings Adjusted EBITDA
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$166M liquidity · $0M/mo burn
Low dilution risk